| Systematic (IUPAC) name | |
|---|---|
| 4-[(dichloroacetyl)(methyl)amino]phenyl furan-2-carboxylate | |
| Clinical data | |
| Trade names | Entamide |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| Pregnancy cat. | No available data |
| Legal status | Not approved (US, CA) |
| Routes | Oral |
| Pharmacokinetic data | |
| Bioavailability | 90% (diloxanide) |
| Metabolism | Hydrolyzed to furoic acid and diloxanide, which undergoes extensive glucuronidation |
| Half-life | 3 hours |
| Excretion | Renal (90%), fecal (10%) |
| Identifiers | |
| CAS number | 3736-81-0 |
| ATC code | P01AC01 |
| PubChem | CID 19529 |
| DrugBank | DB08792 |
| ChemSpider | 18400 |
| KEGG | D02480 |
| ChEMBL | CHEMBL1334860 |
| Chemical data | |
| Formula | C14H11Cl2NO4 |
| Mol. mass | 328.147 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| (what is this?) (verify) |
|
Diloxanide furoate is an anti-protozoal drug used in the treatment of Entamoeba histolytica[1] and some other protozoal infections.
A 13-year study conducted by the United States Center for Disease Control between 1977 and 1990 found that this drug had a low incidence of side effects and was successful in treatment of 86% of asymptomatic carriers of Entamoeba histolytica. [2]
United States: Not currently approved for use. A CDC study authorized the use of this drug in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990. [2]
|
||||||||||||||||||||||||||||||||||||||